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Purpose: To evaluate the use of desipramine in the treatment of overactive bladder (OAB).
Materials and Methods: We retrospectively evaluated 43 patients who were treated with
desipramine for OAB refractory to antimuscarinic therapy. These OAB patients were stratified by the presence or absence of bladder pain.
Results: Forty-three patients were evaluated with a mean follow up time of 12.2 ± 4.6 months.
The mean age of the patients was 71 ± 16 years. Twelve patients (28%) discontinued desipramine, 9 due to perceived lack of efficacy, 2 due to central anticholinergic side effects, and
1 due to the development of oropharyngeal sores. Patients were stratified into two subgroups
based upon treatment with desipramine for OAB alone (n = 29) or OAB and bladder pain (n
= 14). There was no difference between the groups in regard to sex (P = .34), prior history of
radiation (P = .19), side effects (P = .16), and specifically evaluated central anti-cholinergic
side effects (P = .66). There was no statistical difference in the self-reported success rate of
the medication (P = .48). In the OAB plus bladder pain subgroup, 71% of patients reported
improvement in their pain. Overall, 13 (30%) patients had history of prior pelvic radiation
and 10 of those (77%) reported improvement with desipramine.
Conclusion: Desipramine is a potential useful treatment for patients with OAB. In addition,
it can be used in patients with OAB and bladder pain and patients with complex OAB such
as OAB caused by pelvic radiation.
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O

upon established AUA guidelines.(10) Patients were informed

to range between 11.8% and 14%, slightly lower in men

tics, and patient-reported outcomes, and side-effect profiles

than in women.(2,3) This symptom profile has been shown in

while taking desipramine were retrospectively reviewed. Pa-

several studies to increase with age.(2,4,5) The incidence in-

tients were followed serially at monthly visits to assess the

creases from 10.5% for patients aged 18-24, up to 21.9% for

therapeutic effects as well as side effects of the medication

those aged greater than 65 years.(3) In elderly patients who

regimen. Data collection and analysis for this study was ap-

fail conservative treatments for OAB, pharmacologic man-

proved by the Institutional Review Board (IRB) and all pa-

agement can be challenging.(6) Traditionally, anticholinergic

tient data was stored in a secure patient de-identified database

agents such as oxybutynin are used as a first-line pharma-

in accordance with the IRB approval.

INTRODUCTION
veractive bladder (OAB) is a condition character-

about the off-label use of desipramine for this purpose. An

ized by increased urinary urgency, with or without

inclusion criterion was OAB refractory to prior anticholin-

incontinence.(1) Its prevalence has been estimated

ergic treatment. Patient demographics, clinical characteris-

cologic treatment.(7) If the patient symptoms are refractory
to treatment with traditional first-line anticholinergic agents,

Statistical Analyses

tricyclic antidepressants (TCAs) such as amitriptyline and

All statistical analyses were conducted on Microsoft Excel

imipramine can be prescribed. However, a limitation of all

2007 platform. Continuous and categorical variables were

anticholinergic agents on the market is their lack of specific-

analyzed using Mann-Whitney U test and Chi-Squared test,

ity for muscarinic receptors of the bladder. As a result, cen-

respectively.

tral anticholinergic side-effects including memory defects,
fatigue, and impaired balance can often be experienced.(6)

RESULTS

Furthermore; elderly patients are particularly vulnerable to

Forty-three patients were evaluated who were prescribed

these side-effects associated with the central anticholinergic

desipramine after failing treatment with at least one anti-

effects of TCAs. This is due in part to an increased anticho-

muscarinic agent. Failure from an antimuscarinic agent was

linergic load, polypharmacy, a natural age-related decline

determined through chart review. The initial dosing of all pa-

in cholinergic function, and declining function of the blood

tients was 10 mg. The range of final dosing was 10 mg to 75

brain barrier.(6)

mg. Two patients (5%) dosages were raised to 25 mg, 3 (7%)

Desipramine is an active metabolite of imipramine. It is dis-

to 50 mg and 1 (2%) to 75 mg. Their dosages were raised

tinguished by the presence of only one n-methyl group on

based on clinical evaluation of patient self-reported symptom

its side chain.(7) It has been shown in several studies to have

benefit and side effects. The mean age of the patients was 71

less central nervous system (CNS) side effects than other

± 16 years (Table 1). Twenty-three patients (53%) were male

TCA agents including imipramine and amitriptyline.(7-9) No

and 20 (47%) were female. Overall, 13 (30%) patients had

published study has evaluated the use of desipramine as a

history of prior pelvic radiation and 10 of those (77%) re-

treatment for OAB. Herein, we report on our experience with

ported improvement with desipramine. Thirty-one (72%) of

desipramine for the primary treatment of symptomatic OAB

the original 43 patients continue to take desipramine as pre-

with the goal of minimizing CNS-related side-effects.

scribed at a mean follow up of 12.2 ± 4.6 months, reporting
clinical benefit and improvement of their OAB symptoms.

MATERIALS AND METHODS

Twelve patients (28%) discontinued desipramine, 9 (75%)

Data Collection

due to perceived lack of efficacy, 2 (17%) due to central an-

Data was prospectively collected on patients that were pre-

ticholinergic side effects, and 1 (8%) due to the development

scribed desipramine by a single physician (GHW) for the

of oropharyngeal sores. The average duration of compliant

second-line treatment of OAB over a two year period span-

use of the medication in these patients who discontinued

ning between 2010 and 2011. Diagnosis of OAB was based

use was calculated at 6 ± 3.4 months. Overall, 12 patients
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Table 1. Baseline characteristics of patients prescribed desipramine
for overactive bladder.

Table 2. Comparison of patients prescribed desipramine for overactive
bladder only and for overactive bladder plus bladder pain.

Patients
Number

43

Male

23

Female

20

Age ± SD, years

71 ± 16

Side effects, n (%)

12 (28)

Central anticholinergic side effects, n (%)

7 (16)

Prior pelvic radiation, n (%)

13 (30)

Patients doing well on medication, n (%)

31 (72)

Number

Key: SD, standard deviation.

OAB Only

OAB and
Bladder Pain

P

29

14

.19

Male

18

5

Female

11

9

Age ± SD, years

68.4 ± 18.0

76.7 ± 8.5

.05

Side effects, n (%)

6 (21%)

6 (43)

.16

Central anticholinergic side effects, n (%)

4 (14)

3 (21)

.66

With prior pelvic radiation, n (%)

9 (31.0)

4 (28.6)

.34

Patients doing well on medication, n (%)

22 (75.8)

9 (64.3)

.48

Key: SD, standard deviation; OAB, overactive bladder.

reported side effects from the medication, the most common

simultaneously prescribed two or more medications with an-

being dry mouth (n = 5, 42%), constipation (n = 2, 17%), and

ticholinergic activity.(3,13) In addition, the elderly may have

fatigue (n = 3, 25%).

diminished efficiency of drug metabolism and elimination,

Furthermore, patients were stratified into two subgroups

leading to an increased anticholinergic “load” effectively.(14)

based upon desipramine treatment for OAB alone (n = 29) or

Delirium can be caused by blockage of brain muscarinic re-

OAB combined with bladder pain (n = 14) (Table 2). There

ceptors and drugs with anticholinergic activity are the most

was no difference noted between the groups in regard to sex

common cause of drug-induced delirium.(15,16)

(P = .34), prior history of pelvic radiation (P = .19), side ef-

Among the TCA agents, desipramine has been noted to have

fects (P = .16), and specifically assessed central anticholin-

the least anticholinergic affect.(15) In initial clinical trials, it

ergic side effects (P = .66). However, the OAB plus bladder

was noted to have less CNS side effects when compared to

pain group was significantly older (P = .05). There was no

imipramine.(9) These findings were corroborated in two sub-

statistical difference in the self-reported success rate of the

sequent studies.(7,11) A randomized control trial of 20 patients

medication (P = .48). In the OAB plus bladder pain group 10

comparing imipramine and desipramine use for the treatment

(71%) patients reported improvement in their pain in addi-

of major depression, found that although desipramine was

tion to OAB symptoms.

not superior to imipramine in its treatment of depression
symptoms, it is less likely to produce central anticholinergic

DISCUSSION

side effects such as headache, tremors, and dizziness.(10) Di

CNS side effects from treatment with anti-muscarinic agents

Mascio and colleagues enrolled 7 blinded subjects who were

include headache, fatigue, dizziness, cognitive impairment,

given either a dose of imipramine (50 mg, 100 mg or 200

(11)

confusion, and insomnia.

TCAs have similar side-effects
(11-13)

due to their adjunct anticholinergic properties.

mg) desipramine (50 mg, 100 mg, and 200 mg) or a placebo.

More el-

Subjects were then tested performing various cognitive and

derly patients are more likely to suffer from OAB and are

visou- motor tasks such as typing, aiming and performing

also more likely to experience anticholinergic side-effects

calculations. They found that imipramine produced marked

(12)

from the medications used to treat their symptoms.

This

impairment in intellectual and visuo-motor function in com-

increased risk is commonly attributed, at least in part, to

parison to desipramine.(7)

polypharmacy which is more prevalent in this population

Desipramine has also been compared to amitriptyline in head-

with more comorbidity. Gardner and colleagues estimated

to-head investigation. In a double blinded crossover study by

that between 21% and 32% of nursing home residents are

Blackwell and colleagues, nine healthy female volunteers
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were given three different doses of desipramine (25 mg, 50

arm design which cannot fully access the comparative effi-

mg, and 100 mg), three different doses of amitriptyline (25

cacy of desipramine as a single-agent treatment modality for

mg, 50 mg, and 100 mg) and placebo. The patients then were

OAB. Future, prospective randomized studies are needed on

asked to rate their sedation on Clyde Mood Scale. Amitrip-

this topic to fully elucidate the utility and side-effect profile

tyline was noted to produce more sedation at all levels and

of desipramine over other agents as a treatment option for

(8)

was clinically significant at 50 mg (P < .01).

In a study

OAB.

of pigeons by Vaillant, the central anticholinergic effects of
desipramine, amitriptyline and imipramine were assessed

CONCLUSION

by measuring their ability to mask the central muscarinic ef-

Our experience to date has demonstrated desipramine as a

(17)

fects of physostigmine.

Desipramine was found to be the

useful potential treatment for patients with OAB refractory to

least effective in CNS function of the TCAs tested, requir-

first-line antimuscarinic therapy, possibly providing an alter-

ing the highest dose to reverse the central muscarinic activity

native treatment modality with a mechanistically minimized

of physostigmine. Furthermore, in a study by Abernethy and

risk of CNS side-effects compared to other TCAs.

colleagues, metabolic clearance of desipramine was found to
be less affected by increasing age than that of imipramine.(18)

CONFLICT OF INTEREST

In consideration of its decreased central anticholinergic ac-

None declared.

tivity, we sought to report on the use of desipramine for patients with OAB refractory to treatment with first-line antimuscarinic agents. To our knowledge this is the first study
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